Investment analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research note issued on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
TTNP stock opened at $3.23 on Friday. Titan Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $14.80. The business’s fifty day moving average is $3.72 and its 200-day moving average is $4.94.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- How to Invest in Insurance Companies: A Guide
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- Where to Find Earnings Call Transcripts
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- What Are Dividend Champions? How to Invest in the Champions
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
